3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
178
Endometrial Neoplasms
110
Uterine Cervical Neoplasms
100
Breast Neoplasms
58
Colorectal Neoplasms
49
Fallopian Tube Neoplasms
45
Carcinoma, Non-Small-Cell Lung
42
Neoplasms
36
Pancreatic Neoplasms
34
Prostatic Neoplasms
27
Neoplasm Metastasis
27
Stomach Neoplasms
25
Melanoma
25
Squamous Cell Carcinoma of Head and Neck
22
Lung Neoplasms
22
Esophageal Neoplasms
21
Carcinoma, Ovarian Epithelial
20
Triple Negative Breast Neoplasms
19
Carcinoma, Renal Cell
18
Urinary Bladder Neoplasms
17
Head and Neck Neoplasms
17
Colonic Neoplasms
16
Carcinoma, Transitional Cell
16
Carcinoma, Hepatocellular
15
Small Cell Lung Carcinoma
14
Sarcoma
14
Cholangiocarcinoma
14
Uterine Neoplasms
13
Vulvar Neoplasms
12
Rectal Neoplasms
12
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Gynecologic
×
30 days
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled